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Abstract: Snakebite is classified by the WHO as a
neglected tropical disease. Envenoming is a significant
public health problem in tropical and subtropical regions.
Neurotoxicity is a key feature of some envenomings, and
there are many unanswered questions regarding this
manifestation. Acute neuromuscular weakness with respi-
ratory involvement is the most clinically important
neurotoxic effect. Data is limited on the many other
acute neurotoxic manifestations, and especially delayed
neurotoxicity. Symptom evolution and recovery, patterns
of weakness, respiratory involvement, and response to
antivenom and acetyl cholinesterase inhibitors are vari-
able, and seem to depend on the snake species, type of
neurotoxicity, and geographical variations. Recent data
have challenged the traditional concepts of neurotoxicity
in snake envenoming, and highlight the rich diversity of
snake neurotoxins. A uniform system of classification of
the pattern of neuromuscular weakness and models for
predicting type of toxicity and development of respiratory
weakness are still lacking, and would greatly aid clinical
decision making and future research. This review attempts
to update the reader on the current state of knowledge
regarding this important issue.
Introduction
Snakebite is a neglected tropical disease of global importance
[1]. Kasturiratne et al. (2008) estimated that annually at least 1.2
million snakebites, 421,000 envenomings, and 20,000 deaths occur
due to snakebite worldwide [2]. The actual figures are likely to be
much higher than these estimates. A study in a rural Sri Lankan
community found that nearly two-thirds of snakebite related
deaths are not reported in hospital-based data [3]. A nationally
representative survey in Bangladesh suggested that incidence of
snakebite is much higher than previously estimated [4]. Data from
the Million Deaths Study in India estimates that snakebite deaths
are more than 30-fold higher than recorded in official hospital
returns [5].
Snakebite-related mortality is highest in resource-poor coun-
tries, and is directly related to socioeconomic indicators of poverty
[1]. The highest burden of morbidity and mortality related to
snakebite is seen in the rural poor communities of tropical
countries in South Asia, Southeast Asia, and sub-Saharan Africa
[2,6,7]. Increased exposure to snakes due to traditional agricul-
tural practices, lack of good health care services, poor access to
available services, influence of health-seeking behaviour on
accessing the available health care services, and lack of effective
antivenom all contribute to this [2,8].
Neurotoxicity is a well-known feature of envenoming due to
elapids (family Elapidae) such as kraits (Bungarus spp.) [9–28],
cobras (Naja spp.) [9,14,20,21,29–39], taipans (Oxyuranus spp.) [40–
46], coral snakes (Micrurus spp.) [47–51], death adders (Acanthophis
spp.) [52–54], and tiger snakes (Notechis spp.) [55–57]. It has also
been well described with pit vipers (family Viperidae, subfamily
Crotalinae) such as rattlesnakes (Crotalus spp.) [58–67]. Although
considered relatively less common with true vipers (family
Viperidae, subfamily Viperinae), neurotoxicity is well recognized
in envenoming with Russell’s viper (Daboia russelii) in Sri Lanka and
South India [9,68–75], the asp viper (Vipera aspis) [76–82], the
adder (Vipera berus) [83–85], and the nose-horned viper (Vipera
ammodytes) [86,87].
Acute neuromuscular paralysis is the main type of neurotoxicity
and is an important cause of morbidity and mortality related to
snakebite. Mechanical ventilation, intensive care, antivenom
treatment, other ancillary care, and prolonged hospital stays all
contribute to a significant cost of provision of care. And ironically,
snakebite is common in resource-poor countries that can ill afford
such treatment costs. The cost of neurotoxic envenomation is
easily overlooked in the face of high mortality, and surprisingly,
there are few data on the cost of caring for patients with
neurotoxic envenomation.
Several other acute neurological features are reported after
snake envenomation, which are likely to be due to direct
neurotoxicity. These have not been well studied, with available
data being mostly confined to case reports, and their potential
pathophysiological mechanisms remain unclear. Neurological
manifestations can also result from non-neurotoxic effects of
envenoming, such as cerebral haemorrhage and infarction due to
coagulopathy, and myotoxicity. This article will focus only on the
direct neurotoxic effects of envenoming.
There are many challenges to the study of neurotoxicity after
snakebite. There is considerable variation between individual
patients in the clinical manifestations following envenoming by
any particular species. Clinical presentations of neurotoxicity are
likely to be colored by the emotional response to a snakebite,
neurological changes related to hypotension, shock and other
organ dysfunction (such as renal impairment), and by the non-
neurotoxic neurological manifestations of envenoming such as
those due to coagulopathy. Comparing findings from different
studies is difficult, as there is a lack of uniformity in description or
grading of neuromuscular weakness, or in assessment of response
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to treatment. Interpretation of neurophysiological findings is also
difficult as different methodologies have been used between
studies.
The effects of a bite from one snake species can also vary, as
venom constituents in one species may vary seasonally, geograph-
ically, as well as ontogenetically, and some venoms contain a
number of different neurotoxins.
Accurate case definition is the key to meaningful interpretation
of available data and comparison between studies. However, this is
hampered by the difficulties in identifying envenoming snakes,
which have been previously highlighted [88–91]. Previous studies
on snake identification have yielded variable results [92,93].
Immunodiagnosis of snake venom antigen is the most reliable way
of identifying the biting species, but cost and availability issues
preclude its use in the resource-poor settings where snakebite is
common [88–91]. Identification of the killed snake by trained
health staff is perhaps the best alternate way, but snake
identification without specific training can be incorrect and can
potentially lead to serious mistakes in management. Also, rates of
snake capture are low in most series, varying from 5–30% [14,94–
96]. Use of a clinical scoring system [89] or a syndromic
classification [90] has been suggested to improve snake identifi-
cation in the community setting, but these approaches have their
own drawbacks.
Methodology
We searched PubMed with varying combinations of the search
terms ‘‘snake bite,’’ ‘‘snake envenoming,’’ ‘‘snake venom,’’
‘‘neurotoxicity,’’ ‘‘neurology,’’ and ‘‘neurological manifestations.’’
We acquired only English-language articles. We also obtained
articles on ‘‘neuromuscular junction’’ and ‘‘neuromuscular block.’’
Additional related articles were obtained from citation tracking of
retrieved articles and tracking of ‘‘related citations’’ in PubMed.
Altogether, 624 titles and abstracts were screened, and 287 full
articles were retrieved and read by a single author (UKR) for data
acquisition. The reference list was further modified following
reviewers’ comments.
Pathophysiological Basis of Neuromuscular
Paralysis
The peripheral neuromuscular weakness after snakebite results
from defective neuromuscular junction (NMJ) transmission. It is
pertinent to briefly review the current knowledge on NMJ
transmission and neuromuscular block, to better understand the
effects of snake venom at the NMJ [97–104] (Figure 1).
Neuromuscular Transmission and Neuromuscular
Block
At the pre-synaptic level, the motor nerve axon terminal is
responsible for the synthesis, packaging, transport, and release
of the neurotransmitter acetylcholine (ACh). Release of ACh
in response to an incoming nerve action potential is triggered
by the opening of voltage-gated calcium channels and the
influx of calcium ions. Increased intracellular calcium
concentration triggers a cascade of events that leads to the
formation of a fusion complex made up of SNARE (Soluble
N-ethylmaleimide-sensitive-factor Attachment REceptor) pro-
teins, which enables fusion of ACh vesicles to the nerve
terminal membrane and ACh release [98–102,104]. Nicotinic
acetylcholine receptors (nAChRs) at the nerve terminal (pre-
synaptic neuronal autoreceptors -a3b2) facilitate release of
increasing quantities of ACh, by mobilising ACh vesicles from
a reserve pool to a releasable pool, in response to high
frequency stimulation via positive feedback systems [98–100].
Interference with neuromuscular transmission at a pre-
synaptic level can occur at voltage-gated calcium channels
(e.g., Lambert Eaton myasthenic syndrome), SNARE proteins
(e.g., botulism), potassium channels (e.g., neuromyotonia), or
at the neuronal nAChRs.
ACh released from the nerve terminal diffuses rapidly across the
synaptic cleft. Degradation of ACh at the synaptic cleft by acetyl
cholinesterase (AChE) is necessary for the termination of its action.
At the post-synaptic level, ACh binds to muscle nAChRs (adult
or mature type—a1b1ed) on the post-synaptic membrane.
nAChRs are ligand-gated ion channels, and their activation by
ACh leads to an influx of sodium and calcium cations,
accompanied by efflux of potassium ions through potassium
channels, and produces an end-plate potential. If adequate ACh is
released, this end-plate potential is propagated by the opening of
sodium channels along the perijunctional zone and muscle
membrane and initiates calcium release and muscle contraction
[98–100,102].
Neuromuscular block at the post-synaptic level is classified
into non-depolarising and depolarising types. Depolarising
neuromuscular blocking agents (NMBAs) (such as suxametho-
nium) bind irreversibly to the post-synaptic muscle nAChRs,
and produce a non-competitive block, which is not reversed by
acetyl cholinesterase inhibitor drugs (AChEIs). Depolarising
NMBAs initially produce excessive depolarisation [97], which
can be seen as muscle fasciculations [102]. This is followed by
secondary changes responsible for muscle paralysis such as
receptor desensitisation, inactivation of and blockage of
voltage-gated sodium channels, and alterations in ion perme-
ability of the membranes [97,98]. Non-depolarising NMBAs
(such as curare and its derivatives—d-tubocurarine, pancur-
onium, atracurium), in contrast, competitively inhibit ACh
binding to the post-synaptic muscle nAChRs, and produce a
competitive type of block. They repetitively associate with and
dissociate from the ACh binding sites, rather than producing
prolonged binding, and therefore can be displaced by ACh
[97]. Blockade, therefore, can be reversed by AChEIs (such as
edrophonium, neostigmine, and pyridostigmine) which act by
increasing the available ACh at the synaptic cleft. The nAChR
has two ligand binding sites, and both must be simultaneously
occupied by ACh for the receptor to be active. The occupation
of a single binding site by one molecule of a NMBA would
therefore effectively ‘‘block’’ the receptor [98–100,102]. Non-
depolarising NMBAs, however, in addition have been shown to
produce pre-synaptic effects by binding to the pre-synaptic,
neuronal nAChRs (a3b2) [97–99,105,106], and this finding has
challenged the traditional simplistic concept of pre-synaptic
and post-synaptic block. Neurophysiologically, this dual effect
is reflected by the combination of reduction in twitch
amplitude (due to blockade of post-synaptic muscle nAChRs)
and fade of the twitch height responses on repetitive (train-of-
four or tetanic) stimulation (due to blockade of pre-synaptic
neuronal nAChRs) [97,98,100]. Depolarising NMBAs, in
contrast, only produce reduction in the twitch amplitude, but
do not produce the tetanic or train-of-four (TOF) fade [98–
100]. Non-depolarising block also produces a characteristic
post-tetanic potentiation following high frequency (tetanic)
stimulation [99,100,102,107]. NMBAs are known to impair
NMJ transmission by several additional effects on the nAChRs,
without binding to the receptor binding sites. These include
alteration of receptor dynamics, desensitization, and channel
blockade [102].
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Figure 1. Sites of action of snake neurotoxins and other substances on the neuromuscular junction. Schematic representation of the
neuromuscular junction showing different sites of action of snake neurotoxins, other toxins, and pharmacological substances, and sites of
involvement in disease states (examples indicated where relevant). 1. Synaptic vesicular proteins: Snake toxins: beta-bungarotoxin (Bungarus
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Snake Venom Toxins and Neuromuscular Block
(Table 1, Figure 1)
Traditionally it has been considered that snake venom toxins
cause two types of neuromuscular blockade, pre-synaptic and post-
synaptic; but this view may be oversimplistic and needs to be
reviewed in view of the recent insights into neuromuscular
transmission and descriptions of different patterns of neurotoxicity.
Much of the current understanding of neurotoxicity has come
from animal studies using purified individual toxins.
The pre-synaptically active neurotoxins (beta-neurotoxins—
mostly neurotoxic phospholipase A2 toxins, PLA2s) bind to the
spp.), taipoxin (O. scutellatus); Other toxins: botulinum toxin, tetanus neurotoxin. 2. Voltage-gated calcium channel: Snake toxins: calciseptine
(Dendroaspis spp.), beta- bungaratoxin (Bungarus spp.); Other toxins: omega-conotoxin (marine snail, Conus spp.); Disease states: Lambert-Eaton
myaesthenic syndrome. 3. Pre-synaptic membrane: Snake toxins: phospholipase A2 toxins. 4. Pre-synaptic ACh receptor: Snake toxins:
candoxin (Bungarus candidus); Other toxins: curare; Pharmacological substances: non-depolarising blocking drugs (atracurium). 5. Voltage-gated
potassium channels: Snake toxins: dendrotoxins (Dendroaspis spp.); Disease states: neuromyotonia, Isaacs’ syndrome; Pharmacological substances:
magnesium sulphate, aminoglycosides. 6. Acetylcholine: Lysis by exogenous acetylcholinesterase in snake venom: cobra venom (Naja spp.). 7.
Acetylcholinesterase: Inhibitors of endogenous AChE in snake venom: fasiculins (Dendroaspis spp.). 8. Post-synaptic ACh receptors: Snake
toxins: alpha-bungaratoxin (Bungarus spp.), candoxin (B. candidus), azemiopsin (A. feae), waglerin (T. wagleri ); Other toxins: alpha-conotoxin (marine
snail, Conus spp.); Disease states: myasthenia gravis; Pharmacological substances: depolarising blocking agents (e.g., succinylcholine), non-depolarising
blocking drugs (e.g., atracurium). 9. Voltage-gated sodium channels: Snake toxins: crotamine (Crotalus spp.); Other toxins: pompilidotoxin (wasps),
delta-conotoxin (Conus spp.), tetradotoxin (pufferfish).
doi:10.1371/journal.pntd.0002302.g001
Table 1. Summary of some key animal studies with individual snake neurotoxins.
Toxin
Authors; year;
[reference] Study description Pathological change
Physiological/clinical
effects
Beta-
bungarotoxin
Dixon & Harris;
1999; [108]
In vitro–isolated nerve-muscle
preparation (phrenic
nerve-hemidiaphragm)
in mice; In vivo nerve-muscle
preparation in rats (sciatic
nerve-soleus muscle; e/m:
labeling of AChR,
synapatophysin, or axonal
neurofilament)
1) Depletion of synaptic vesicles (e/m: loss of synpatophysin
immunoreactivity); 2) Destruction of motor nerve terminal
(e/m: mitochondrial damage, Schwaan cell processes invading
synaptic cleft); 3) Degeneration of axons (staining for anti-
neurofilament antibodies): denervation starts at 3 h, 90% by 6 h,
and complete by 24 h; 4) Reinnervation (by anti-synaptophysin
labeling, labeling for axonal neurofilament): all NMJs reinnervated
by 5 days, stable by 7 days, 90% by 14–21 days, reinnervation
with multiple collateral innervation
Early onset paralysis—initial
facilitation (maximal at
30 min), followed by
irreversible failure of NMJ
transmission (max. at
210 min)
Beta-
bungarotoxin
Prasarnpun et al.;
2004; [117]
Rat phrenic nerve-
hemidiaphragm
- NMJ transmission failure—lag
phase of 20–60 min,
complete failure by 120–
240 min
Beta-
bungarotoxin
Prasarnpun et al.;
2005; [109]
Rat soleus muscle; e/m:
NMJs and nAChRs identified;
synaptic proteins
(synaptophysin, SNAP-25,
and syntaxin) labeled; sodium
channels labeled; axon counts
1) 3–6 hours: depletion of synaptic vesicles, mitochondrial
damage, transient upregulation of voltage-gated sodium
channels, reduction in immunoreactivity of synaptic proteins;
2) Degeneration of terminal boutons, with isolation from post-
synaptic membrane by Schwann cell processes, and withdrawal
from synaptic clefts; denervation complete by 12 h; 3)
Reinnervation starts at 3 days, and complete by 7 days.
Progressive increase in the immunoreactivity of SNARE proteins:
75% by 7 days; 4) Persistent axonal loss at 6 months
Flaccid paralysis by 3 h;
Return of function starting by
3 days, and complete by 7
days
Alpha-
bungarotoxin
Lee et al.; 1977;
[106]
In vivo cat sciatic
nerve-tibialis anterior
preparation
- Gradual onset NMJ block—
50% block in 30–60 min; No
fade with tetanic or train-of-
four stimulation; Post-tetanic
facilitation
Taipoxin,
notexin
Cull-Candy et al.;
1976; [111]
Isolated mouse phrenic
nerve-hemidiaphragm
preparation
Nerve terminal damage—depletion of synaptic vesicles,
axoplasmic vacuoles, mitochondrial change, axolemmal
indentations
NMJ block—Initial latency 40–
60 min; maximal 110–
120 min
Notexin,
taipoxin
Harris et al.;
2000; [118]
In vivo rat soleus muscle;
e/m: labeling of AChR and
axonal neurofilament
1) Nerve terminal degeneration (depletion of synaptic vesicles,
mitochondrial damage): start at 1 h, 70% by 24 h; 2) Axonal
degeneration; 3) Reinnervation start at 2–3 days, 88% by
5 days, complete by 21–28 days; 4) Abnormal collateral
innervation persistent at 9 months
-
Crotoxin Hawgood et al.;
1977; [233]
Isolated mouse phrenic
nerve-hemidiaphragm
preparation
Inhibit quantal release of ACh at nerve terminal -
Candoxin Nirthanan et al.;
2002; [135];
2003; [134]
Rat tibialis anterior muscle;
mouse phrenic nerve-
hemidiaphragm; binding
to muscle nAChRs
- Non-depolarising post-
synaptic block; rapid onset;
reversible with AChEIs;
significant TOF fade
doi:10.1371/journal.pntd.0002302.t001
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motor nerve terminals, leading to depletion of synaptic ACh
vesicles, impaired release of ACh, and later, degeneration of the
motor nerve terminal [108–111]. They produce neuromuscular
block that occurs in three phases: an immediate depression of ACh
release, followed by a period of enhanced ACh release, and then
complete inhibition of NMJ transmission [108,112–116]. The
effects on neuromuscular transmission develop following a latency
period of 20–60 minutes [111,114,117]. The binding of pre-
synaptic toxins to the nerve terminal is irreversible [109,111].
Clinical recovery is slow as it is dependent on regeneration of the
nerve terminal and formation of a new neuromuscular junction
[109,110]. Hence, patients with respiratory failure may need
respiratory support for a longer period before spontaneous
breathing can resume [108,110,113,114,118]. Treatment with
antivenom or AChEIs is unlikely to be effective in pre-synaptic
toxicity [108,109,114,118], and incomplete recovery and delayed
effects are more likely [108].
Pre-synaptic toxins are best illustrated by beta-bungarotoxin (b-
BuTX) of kraits (Bungarus spp.) which predominantly has potent
PLA2 enzymatic activity. Dixon and Harris (1999) first highlighted
the significance of denervation in producing the treatment-
resistant paralysis in krait bite [108]. They showed that beta-
bungarotoxin produces pre-synaptic toxicity characterized by
depletion of synaptic vesicles, destruction of motor nerve
terminals, and axonal degeneration followed by reinnervation
[108]. Prasarnpun et al. (2004, 2005) [109,117] showed that beta-
bungarotoxin produced calcium influx through voltage-gated
calcium channels and increased release of ACh via SNARE-
complex dependent mechanisms leading to depletion of synaptic
vesicles. They were able to demonstrate the correlation between
pathological changes and the neuromuscular transmission failure
induced by beta-bungarotoxin [109]. Rat muscles inoculated with
beta-bungarotoxin were paralysed within 3 hours. This was
associated with loss of synaptic vesicles, mitochondrial damage,
transient upregulation of voltage-gated sodium channels, and a
reduction in immunoreactivity of SNARE proteins (synaptophysin,
SNAP-25, and syntaxin). Between 3 and 6 hours after inoculation,
nerve terminals showed evidence of degeneration. These included
degeneration of terminal boutons, their isolation from the post-
synaptic membrane by Schwann cell processes, and withdrawal
from synaptic clefts. By 12 hours, all muscle fibres were
denervated. Reinnervation began at 3 days with the appearance
of regenerating nerve terminals, a return of neuromuscular
function in some muscles, and a progressive increase in the
immunoreactivity of SNARE proteins. Full recovery occurred at 7
days [109]. Harris et al. (2000) showed that taipoxin (from taipans,
Oxyuranus spp.) and notexin (from the Australian tiger snake,
Notechis scutatus) had effects similar to beta-bungarotoxin [118].
They suggested that all pre-synaptically active PLA2s produce
similar effects [118].
Although the molecular basis of pre-synaptic toxicity induced by
the PLA2s is still not completely understood [119–127], more
recent studies have added significantly to our current knowledge
[119–133]. They have shown that PLA2s from snake venom
neurotoxins produce similar but complex effects on the pre-
synaptic nerve terminal. These include entry into nerve terminals
after binding to specific receptors on the pre-synaptic membrane,
morphological changes such as nerve terminal bulging, changes in
mitochondrial morphology and permeability, increase in cytosolic
calcium levels, changes in expression and interactions of SNARE
proteins, increased vesicle fusion and neurotransmitter release, and
impaired vesicle recycling. Montecucco and colleagues have
shown that the effects produced by four different snake venom
PLA2s (beta-bungarotoxin, taipoxin, notexin, and textilotoxin)
were similar, suggesting a similar mechanism of action for pre-
synaptic neurotoxins. Hydrolysis of the phospholipids of the pre-
synaptic membrane and membrane destabilization by the products
of hydrolysis are likely to be key drivers in this process [122–
124,127,131,132].
The post-synaptically active neurotoxins (alpha-neurotoxins)
bind to the post-synaptic muscle nAChRs. Alpha-neurotoxins
belong to the group of ‘‘three-finger toxins’’ (3FTXs) characterized
by a shared toxin structure resembling three outstretched fingers of
a hand [134–137]. They are classified into three main groups—
long-chain, short-chain, and non-conventional alpha-neurotoxins
[134–137]. They resemble the action of d-tubocurarine (dTC),
and are therefore called ‘‘curare-mimetic’’ neurotoxins. dTC
classically produces a reversible, non-depolarising post-synaptic
block by competitive inhibition of ACh binding to the muscle
nAChR [97]. It also inhibits the pre-synaptic neuronal nAChRs,
producing the characteristic TOF or tetanic fade. However, there
can be significant variations in the effects of the so-called ‘‘curare-
mimetic’’ neurotoxins on the post-synaptic nAChR. Some toxins
(e.g., alpha-cobratoxin) have been shown to produce a compet-
itive, non-depolarising type of post-synaptic blockade similar to
dTC [138,139]. In this type of toxicity, antivenom may facilitate
dissociation of toxin from the ACh receptor and accelerate
recovery [11,110], and a clinical response to AChEIs, similar to
myasthenia, is more likely [140]. Most of the alpha-neurotoxins,
however, bind almost irreversibly to the post-synaptic nAChRs,
even though they produce a non-depolarising type of block
[106,134,136]. Their action, therefore, is not readily reversible by
antivenom or AChEIs. These include most of the long-chain
3FTXs such as alpha-bungarotoxin.
Lee et al. (1977) showed that alpha-bungarotoxin (a-BuTX)
produced a pure post-synaptic, non-depolarising, but almost
irreversible neuromuscular blockade [106]. This was characterized
by slow onset, persistent and dose-dependent progression, lack of
recovery for a long period, and lack of sustained reversibility to
AChEIs. Post-tetanic facilitation was prominent. Tetanic and
TOF fade were not seen, and therefore this differed from the type
of block seen with d-tubocurarine [106]. The lack of tetanic and
TOF fade is attributed to the failure of alpha-bungarotoxin to
block the pre-synaptic neuronal nAChRs [97–99].
The recent insights into NMJ transmission have enabled better
and more comprehensive characterization of the more recently
described toxins. Candoxin, a novel toxin isolated from the venom
of the Malayan or blue krait (Bungarus candidus), is a non-
conventional 3FTX with structural similarities to alpha-bungaro-
toxin [134–136]. However, in contrast to the nearly irreversible
blockade produced by alpha-bungarotoxin, candoxin produces a
readily reversible block of the post-synaptic nAChR. In addition,
candoxin also inhibits the pre-synaptic, neuronal AChRs and
produces tetanic and TOF fade on rapid repetitive stimulation
[134,136].
Although reversibility of blockade would be of crucial impor-
tance in the success of therapeutic interventions, what determines
reversibility seems unclear. Low receptor binding affinity and a
short polypeptide chain length of the toxin molecules have been
postulated as likely reasons, but it is more likely that substitution of
amino acid residues in regions that interact with the AChR may be
responsible [134,136].
Some snake venom toxins interfere with NMJ transmission
through various other mechanisms. Some pre-synaptic toxins,
such as the dendrotoxins from venoms of the Eastern green
mamba (Dendroaspsis angusticeps) and the black mamba (D. polylepis),
enhance ACh release from the nerve terminals by inhibiting
potassium channels and produce a neuromuscular block similar to
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depolarising block [114,141]. A different type of toxin from D.
angusticeps acts as an AChE inhibitor, thus increasing the
availability of ACh at the NMJ. They have been named fasciculins
due to their effect of producing generalized, long-lasting fascicu-
lations [136,142–144].
Snake Venom and Neuromuscular Block
Snake venoms do not contain a homogenous single toxin, but
are complex cocktails of enzymes, polypeptides, non-enzymatic
proteins, nucleotides, and other substances, many of which may
have different neurotoxic properties [91,112,113,116,134,
145,146] (Table 2). The studies of Chang and others of the
Chinese (or formerly Formosan) cobra (Naja atra) venom (1966,
1972) [138,139] highlighted the complexity of multiple actions of
different neurotoxins in the same venom. They demonstrated that
the main neuromuscular blocking effect was due to cobrotoxin,
which produced a curare-like non-depolarising, competitive post-
synaptic block, which was antagonised by neostigmine. It had no
effect on nerve conduction. However, the venom also contained
cardiotoxin, which interfered with axonal conduction and
produced muscle depolarisation [138,139].
Characterization of new toxins continues to add to the rich
diversity of snake venom, and many types of venom are now
known to contain both pre- and post-synaptically active toxins. For
example, a post-synaptic toxin (DNTx-I—Daboia Neurotoxin 1)
has been isolated from the venom of Russell’s viper (Daboia russelii)
[146], in addition to the well-known pre-synaptic PLA2 toxin
[147,148]. Venom of kraits (Bungarus spp.) consists of several
different types of neurotoxins. In addition to the alpha-bungaro-
toxin (post-synaptic block) and beta-bungarotoxin (pre-synaptic
block) already described, it also contains kappa-bungarotoxin
which binds to the neuronal nAChR at the post-synaptic level in
central cholinergic synapses in autonomic ganglia [109,149,150].
Experimental data on physiological, pathological, and ultra-
structural changes due to snake neurotoxins are derived from
studies in animal models, in vitro nerve-muscle preparations, or
preparations of nAChRs. However, such laboratory data may not
accurately reflect the effects of snake venom in humans. It is
known that the effects of envenoming can vary depending on the
bitten species, and this may be due to the snake’s prey preferences.
For example, candoxin from the Malayan or blue krait (B.
candidus), which feeds mainly on rodents and reptiles, preferentially
binds to murine nAChRs rather than to those of chick origin
Table 2. Some examples of toxin diversity in snake venom.
Snake type Toxin Species Type of toxin Neurotoxic effects References
Cobra (Naja spp.) Alpha-cobratoxin N. kaouthia; N.
siamensis
Long-chain
alpha-neurotoxin (3FTX)
1) Bind to post-synaptic muscle nAChRs—produce
reversible, non-depolarising block; 2) Bind to
neuronal a7 nAChRs
[136,137,234]
Cobrotoxin N. atra Short-chain
alpha-neurotoxin (3FTX)
Post-synaptic non-depolarising block [138,139]
Cardiotoxin N. atra 3FTX Blocks axonal conduction, cytotoxicity [138,139]
Toxin-alpha N. nigricollis Short-chain
alpha-neurotoxin (3FTX)
Post-synaptic non-depolarising block [136]
‘‘Weak toxin,’’ WTX N. kaouthia Non-conventional
alpha-neurotoxin (3FTX)
1) Bind to post-synaptic muscle nAChRs—produce
irreversible, non-depolarising block; 2) Bind to
neuronal a7 nAChRs
[136,235]
Krait (Bungarus
spp.)
Alpha-bungarotoxin B. multicinctus Long-chain
alpha-neurotoxin (3FTX)
Bind to post-synaptic muscle nAChRs—produce
irreversible, non-depolarising block
[106,136]
Beta- bungarotoxin Bungarus spp. Phospholipase A2 Pre-synaptic block [108,109,117]
Kappa-bungarotoxin B. multicinctus Kappa-neurotoxin (3FTx) Block neuronal nAChRs in autonomic ganglia [137,149,150,236,237]
Candoxin B. candidus Non-conventional
alpha-neurotoxin (3FTX)
1) Bind to post-synaptic muscle nAChRs—produce
reversible, non-depolarising block; 2) Bind to
neuronal a7 nAChRs
[134–136]
Russell’s viper
(Daboia spp.)
Phospholipase A2
activity
D. russelii Phospholipase A2 Pre-synaptic block [147,148]
Daboia Neurotoxin-1
(DNX-1)
D. russelii Short-chain neurotoxin Post-synaptic block [146]
Viperotoxin-F D. russelii Phospholipase A2 Pre-synaptic block [113,238]
Mamba
(Dendroaspis spp.)
Dendrotoxins—
alpha, delta, I, K
D. angusticeps, D.
polylepis
3FTX Block neuronal voltage-gated potassium
channels—pre-synaptic +/2post-synaptic
effects
[141,200]
Fasciculins D. angusticeps, D.
polylepis
3FTX Inhibit AChE [143,144]
Muscarinic toxins D. angusticeps 3FTX Muscarinic effects by binding to muscarinic AChRs [136,142,204]
Calciseptine D. polylepis Inhibit voltage-gated calcium channels [239]
Rattlesnake
(Crotalus spp.)
Crotoxin C. durissus Phospholipase A2 1) Pre-synaptic block; 2) Post-synaptic effect by
desensitization of nAChR
[116,228,233,240,241]
Mojave toxin C. scutulatus Phospholipase A2 Pre-synaptic ion channel blocker [116,170,242]
doi:10.1371/journal.pntd.0002302.t002
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[135]. Irditoxin from the venom of the brown tree snake (Boiga
irregularis) shows taxa-specific lethal toxicity to birds and lizards,
but not toward mice. In vitro studies showed that it produced
potent post-synaptic toxicity similar to alpha-bungarotoxin at
avian NMJs, but not in mammalian NMJs [151]. Waglerin from
Wagler’s pit viper (Tropidolaemus wagleri) binds more tightly to
mouse nAChRs than to those from rats or humans [152].
Similarly, interspecies differences in sensitivity of nerve-muscle
preparations to pre-synaptic snake toxins have been well
documented [113].
Furthermore, some in vitro studies of toxins have been done
on nAChRs of abcd type, which is the foetal type of nAChR,
in contrast to the adult (or mature) type (abed) of nAChR
normally expressed in the NMJ [135]. It is known that the two
different types of receptors have different opening times and
speeds of ion conductance [97,98]. It is likely that the effects of
toxins on the two different types of receptor, and therefore the
in vivo effects on humans, may be different to what may be
observed in the laboratory. In this context, it is interesting to
note that waglerins from Wagler’s pit viper (Tropidolaemus
wagleri) and azemiopsin from Fea’s viper (Azemiops feae) have
shown specificity toward the ontogenetic state of the nAChR,
with higher binding affinity to the adult (or mature) form than
the foetal form [152–155].
Clinical Manifestations
Acute Neuromuscular Paralysis (Figures 2, 3, 4)
Reported prevalence rates of neuromuscular weakness vary
between series, and with different snake species and different study
settings. As seen from above, each toxin can have a multitude of
effects, venom of one snake species is a mix of multiple toxins, and
venom composition varies between species of same genus. In
addition, intraspecies variations in venom compositions are well
known. It is therefore not surprising that wide variation is seen in
the neurotoxic effects.
Possible methodological differences and lack of uniformity in
description contribute to the large variation between studies, and
make interpretation of data from different studies difficult. Ptosis is
reported in between 70–93% of patients in most series, and
extraocular muscle weakness in 68–82% [9–11,42,73,75,156].
Respiratory muscle weakness is reported in 27–87% [9–
11,25,42,45,156]. Case fatality rates with neurotoxic envenoming
again show wide variation, usually ranging between 4–11%
Figure 2. Respiratory paralysis in neurotoxic envenoming. Sri Lankan patient with severe neurotoxicity and respiratory paralysis being
ventilated following a cobra (Naja naja) bite. (Photograph courtesy of Prof. S. A. M. Kularatne, University of Peradeniya, Sri Lanka. The purpose of the
photograph has been explained to the patient, and consent obtained for potential publication.)
doi:10.1371/journal.pntd.0002302.g002
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[10,11,14,20,25,26,31,42,94,156], but rates as high as 37% have
been reported [20]. Variations in case fatality are likely to be
influenced by many factors including intensity of staff observa-
tion, development of respiratory failure, and availability of
ventilation. Intensive care units are more likely to admit more
severe patients with respiratory involvement [11,26,94,157],
and therefore may have higher mortality rates than less-biased
samples. Delays in accessing ICU care, and lack of adequate
facilities for optimal care in resource-limited areas where
snakebite is common, also would contribute to higher mortality
[20].
The envenoming snake species is highly likely to influence the
clinical presentation and outcome, but many studies have
considered together bites from different snake species
[9,14,26,37,94,156–158]. Such differences are perhaps unavoid-
able as confirming the identity of the envenoming snake is often
difficult. Only a few studies have reported snake identification by
detection of venom antigens [21,30,31,42,45,69,159]. A reason-
ably representative picture of neurotoxicity with different snakes
can only be obtained from studies with larger numbers of
unselected patients admitted to general care units, accurate
species identification, and a focus on bites by a single type of
snake (see Table 3).
Respiratory Muscle Weakness
Many patients with neurotoxicity develop ptosis and extraocular
muscle weakness, but only a few will develop respiratory muscle
weakness. Factors that determine development of respiratory
muscle weakness in some patients are not clear. The traditionally
held view that it is related to the dose of venom and the severity of
envenoming, perhaps modified by antivenom therapy, has not
been adequately addressed. The possibility that distinct patterns of
neuromuscular weakness exist in snake envenomation has not
been studied. A parallel may be drawn with myasthenia gravis
where two forms of weakness, ocular and generalized, are well
known. Extraocular muscles are developmentally, histologically,
ultrastructurally, immunologically, metabolically, and functionally
different to other skeletal muscle groups [160–166]. They have a
mixture of several different fibre types, including singly innervated
fast-twitch fibres and multiply innervated slow-twitch fibres
[160,161,165]. Their NMJs are different, with lower AChR
densities and lower quantal ACh contents [165]. Both adult (abed-)
Figure 3. Bilateral ptosis and facial weakness in neurotoxic envenoming. Sri Lankan patient with bilateral ptosis and facial weakness
following a Krait (Bunagrus caeruleus) bite. (Photograph courtesy of Prof. S. A. M. Kularatne, University of Peradeniya, Sri Lanka. The purpose of the
photograph has been explained to the patient, and consent obtained for potential publication.)
doi:10.1371/journal.pntd.0002302.g003
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and foetal (dbcd-) isoforms of nAChR are expressed in adult
extraocular muscles, unlike in other skeletal muscles
[163,165,166]. It is not surprising that they are involved
differently in various pathological processes. They are prefer-
entially affected in some diseases such as myasthenia and
chronic progressive ophthalmoplegia, and selectively spared in
Duchenne muscular dystrophy and amyotrophic lateral sclerosis
[161,163,164]. There needs to be further study at the molecular
level of the effect of different snake venom neurotoxins on
development of respiratory muscle weakness.
Ptosis and extraocular weakness are commonly reported in Sri
Lankan Russell’s viper envenoming [9,69,72,73,75], but reports of
respiratory involvement are sketchy [9,75].
It is known that different toxins have different affinities to the
two isoforms of muscle nAChRs [152–155] (as described earlier),
but whether this can explain the different patterns of selective
muscle group involvement needs further study.
The natural history of neurotoxic envenomation is likely to
vary with the degree of envenoming and snake species, and
between patients. There are little data on the natural course, as
it can be affected by treatment. In a rare case series of 60
patients with envenoming by the many-banded krait (Bungarus
multicinctus) in Vietnam for whom antivenom was not available,
87% needed mechanical ventilation for a mean of 8 days, the
mean duration of the ICU stay was 12 days, and hospital
mortality was 7% [11].
Neurotoxicity, Type of Snake, and Possible
Geographical Variation
There is a clear variation in the propensity of similar species of
snakes to produce different patterns of neuromuscular weakness in
different geographical locations. For example, the Philippine cobra
(Naja philippinensis) produces more neurotoxicity and less local
swelling [31] compared to other Asian cobras [21,32,38]. There
are several reports of neurotoxicity due to envenoming by Russell’s
viper (Daboia russelii) in Sri Lanka and South India, in contrast to
reports of bites by Russell’s viper from other countries
[7,9,68,69,72–75].
These geographical differences may be due, at least in part, to
interspecies and intraspecies differences in venom compositions.
The venom composition in Russell’s viper in Sri Lanka (Daboia
russelii) and South India (D. russelii) was found to be different from
that found in Pakistan (D. russelii), Thailand (D. siamensis), and
Taiwan (D. siamensis) [167]. However, even with similar venom
compositions, the difference between clinical reports from Sri
Lanka and India are striking. While neurotoxicity has been
reported in a majority (,80%) of Sri Lankan patients with
Figure 4. Neurotoxicity in Russell’s viper envenoming. Sri Lankan farmer with Russell’s viper (Daboia russelii) envenoming: tissue necrosis at
bite site, haematuria, and bilateral ptosis. (Photographs courtesy of Prof. S. A. M. Kularatne, University of Peradeniya, Sri Lanka. The purpose of the
photographs has been explained to the patient, and consent obtained for potential publication.)
doi:10.1371/journal.pntd.0002302.g004
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Russell’s viper envenoming [69,73,75], there are only isolated case
reports from India [7,74]. Although these differences may be
attributed to poor reporting, a prospective case series of viper bites
from India did not report any neurotoxicity [168]. In addition,
there are several reports of fascinating regional variations in
venom composition and potency from the same species (intraspe-
cies variation) within the same country, e.g., Russell’s viper (Daboia
russelii) in India [147,169], the Mojave rattlesnake (Crotalus
scutulatus) in the United States [170], the asp viper (Vipera aspis)
in France [76,81], and tiger snakes (Notechis scutatus) in Australia
[171].
Neurophysiological Changes in Neuromuscular
Paralysis
Surprisingly few human data are available on the acute
neurophysiological changes after snakebite. The available data
mainly examine the defective transmission at the neuromuscular
junction, with evidence for both pre-synaptic and post-synaptic
defects (see Table 4). Interpretation of the findings from these
studies is difficult, as different methodologies have been used (e.g.,
different rates of repetitive stimulation). Several articles describe
neurophysiological changes, but carry insufficient details of the
neurophysiological assessments [172]. There are very little data on
single-fibre EMG findings, which would best document defective
NMJ transmission.
Treatment of Neuromuscular Paralysis in Snake
Envenoming (Table 5)
Antivenom in Neurotoxicity
There are many unresolved questions regarding the use of
antivenom in snake envenomation–related neurotoxicity, and
available reports show conflicting results. Differences in study
methodology (species of snake, single snake type or ‘‘mixed bag,’’
presence of respiratory paralysis, severity of envenoming, delays to
treatment) are likely to contribute significantly to the reported
variations in response to treatment. In addition, such variations
may well be related to the differences between pre-synaptic and
post-synaptic types of toxin in snake venom, and also to the
specificity of antivenom to the envenoming snake species. How
much of the reported recovery may be attributable to spontaneous
recovery is not clear, and there are a number of reports of recovery
from neuromuscular paralysis without antivenom [11,173,174].
There are few well-documented reports of benefit with antivenom
[18,48]. Even in such reports, benefits have not been consistent
and were seen only in some patients. In contrast, many of the well-
documented case series report no benefit with antivenom in
neuromuscular failure [10,21,27,30,42,61]. However, several
studies have observed improvement in neurotoxicity when
antivenom had been administered very early [40,42,54,69].
Antivenom cannot neutralise bound venom, and can be effective
only if given early enough to neutralise circulating venom before it
binds to target sites [42,94]. It is likely that early administration is
critical for success. Placebo-controlled randomized clinical trial
data of antivenom in neurotoxicity are lacking. In a randomized
double-blind trial in Philippine cobra (Naja philippinensis) enven-
oming, antivenom was not found to be effective [30]. However, in
a recent non-randomized trial from Vietnam, antivenom was
reported to be beneficial in patients with envenoming by the
many-banded krait (B. multicinctus) [175]. A key limitation in this
study was that patients given antivenom were compared with a
group of patients treated during an earlier period for whom
antivenom was not available (historical control). In experimental
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conditions, toxin-specific antibodies have been shown to reverse
neurotoxic effects. Gatineau et al. (1988) reported that specific
antibodies against Naja nigricollis toxin-alpha were able to reverse
toxin binding to the AChRs and the resultant neuromuscular
paralysis [176].
Acetylcholinesterase Inhibitors (AChEIs,
Anticholinesterases) in Neurotoxicity
Neuromuscular weakness, especially due to non-depolarising
post-synaptic blockade, has similarities to myasthenia in pathophys-
iology, and it is theoretically plausible that AChEIs are effective in
this type of neurotoxic envenoming. However, the evidence for
benefit of AChEI is conflicting. This may well be due to the
confounding effects of any natural recovery, co-administered
antivenom, and different types of envenomation by different species.
There are several reports of benefit from AChEIs
[18,20,30,35,51,54,177–181]. Some reports suggest that an
edrophonium test (Tensilon test) can be used to predict the
response to treatment with the longer-acting neostigmine [35].
Two small clinical trials have shown benefit with edrophonium,
and both were in Philippine cobra (Naja philippinensis) envenoming
[30,35]. There are several reports of lack of benefit with AChEIs
in envenoming by kraits [15,21,24,27], taipans [46], and coral
snakes [47].
It is likely that a good response to AChEIs is seen only in the
competitive, reversible type of post-synaptic toxicity [51]. Reports
of benefit with AChEIs in envenoming by snakes producing
predominant pre-synaptic toxicity are unusual [18]. Similarly,
antivenom is likely to be effective only in the competitive,
reversible type of post-synaptic toxicity. Well-controlled clinical
trials with proper snake identification are urgently needed to
identify which patient groups will benefit from these potentially
beneficial treatments, and equally importantly, to identify patients
for whom they should not be given. Currently, it is routine practice
to administer antivenom to all patients with neurotoxic envenom-
ing, with little evidence of benefit, perhaps based on anecdotal
reports of persistent neuromuscular problems in those not
receiving antivenom [42]. Antivenoms used in developing
countries are known to produce adverse reactions in 30–80% of
patients [159,182], and reactions can be seen in up to 25% even in
Table 4. Some human studies with neurophysiological findings in snake neurotoxicity.
Author; year; no. of patients;
[reference] Snake spp. Neurophysiological findings Interpretation
Watt et al.; 1986; n = 2 (out of 10); [35] N. philippensis Decremental response with 5 Hz RNS Non-depolarising, competitive post-
synaptic block
Singh et al.; 1999; n = 12; [23] B. caeruleus Reduction in CMAP amplitudes on motor nerve
stimulation; decremental response to 3 Hz RNS
Both pre-synaptic and post-synaptic
effects
Connolly et al.; 1995; n = 3; [44] O. scutellatus Reduction in CMAP amplitudes on motor nerve
stimulation; decremental response to 5 Hz RNS with
post-activation potentiation followed by exhaustion;
blocking and increased jitter with single-fibre EMG
Pre-synaptic defect
Trevett et al.; 1995; n = 24; [45] O. scutellatus Reduction in CMAP amplitudes on motor nerve
stimulation; reduction in SNAP amplitudes on sensory
nerve stimulation; decremental response to 3 Hz RNS;
post-tetanic potentiation followed by exhaustion
Pre-synaptic defect
(CMAP, compound muscle action potential; RNS, repetitive nerve stimulation; EMG, electromyography; SNAP, sensory nerve action potential).
doi:10.1371/journal.pntd.0002302.t004
Table 5. Summary of studies on interventions in neurotoxic envenoming.
Intervention
Author; year;
[reference] Snake spp. No. of pts Method Outcome
Antivenom Agarwal et al.;
2005; [94]
mixed 55—needing
ventilation
Low-dose vs. high-dose
antivenom
No difference between high and low
doses
Antivenom Ha et al.; 2010; [175] B. multicinctus 81 Non-randomized,
controlled trial
(historical control)
Antivenom effective—reduces
duration of weakness, ventilation, and
ICU stay
Antivenom vs.
edrophonium
Watt et al.; 1989; [30] N. philippensis 8 Randomized,
double-blind trial
Antivenom not effective;
Edrophonium effective
Antivenom;
edrophonium
Phillips et al.; 1988; [69] D. russelii 23 Descriptive case series Antivenom not effective;
Edrophonium not effective
Antivenom and
neostigmine
Anil et al.; 2010; [27] B. caeruleus 54 Descriptive case series Antivenom not effective; Neostigmine
not effective
Edrophonium Watt et al.; 1986; [35] N. philippensis 10 Randomized, placebo-
controlled, double-blind,
cross-over trial
Edrophonium effective—with
improvement in clinical and
neurophysiological parameters
Edrophonium and
3,4-DAP
Trevett et al.; 1995; [46] O. scutellatus 50 Placebo-controlled trial No significant improvement with
edrophonium or 3,4-DAP
doi:10.1371/journal.pntd.0002302.t005
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developed countries [182]. Although symptoms are mild in most
cases, severe systemic anaphylaxis may develop, and further
understanding of their harm-benefit balance is important.
Acute Neurotoxicity—Other Neurological
Manifestations
Several other interesting acute neurological features have been
reported after snake envenomation, which are likely to be direct
neurotoxic effects. The mechanisms of many of these acute
manifestations are not clear, and there has been no systematic
study of these in a large series.
Myokymia has been reported mainly from the United States
following rattlesnake (Crotalus spp.) envenoming, providing
further evidence of variation in neurotoxicity with species and
geographical differences [60–64,66]. Respiratory failure devel-
oped in some patients who had myokymia involving the
shoulders or chest, perhaps due to underlying diaphragmatic
involvement [60]. Myokymia is believed to be due to a
biochemical effect on axonal ion channels leading to increased
peripheral nerve excitability [60,64]. Crotamine in South
American rattlesnake (Crotalus spp.) venom has been shown to
act on voltage-gated sodium and potassium channels [183–189],
and similar molecules may be responsible for the myokymia in
envenoming by North American rattlesnakes (Crotalus spp.).
Inhibition of pre-synaptic voltage-gated potassium channels is
seen in neuromyotonia, which is an autoimmune disorder
presenting with continuous fasciculations. It would be interesting
to see whether a similar mechanism exists in myokymia due to
rattlesnake envenoming [114].
There are several reports of central effects such as drowsiness,
coma, and loss of brainstem reflexes following snakebite. Many of
them are isolated case reports with poor snake identification [190–
192]. Assessment of central effects due to direct neurotoxicity can
be difficult, as similar effects can be produced by cerebral
haemorrhage and ischaemia in snake envenoming, seen especially
with viperid bites. Appropriate neuroimaging would be important
to exclude these effects.
A large series of common krait envenoming has reported
altered consciousness in 64% of patients, and deep coma in 17%
[10]. Drowsiness was common among children with cobra bites
[37]. Seizures have been noted in several reports [9,73,94].
Alterations in smell and taste have been reported in envenoming
by several snake species [67,193,194], and whether these are
central effects or due to peripheral cranial nerve involvement is
not clear.
New studies shed light on the possible diverse effects of snake
neurotoxins beyond the neuromuscular junction, and there are
several reports of their actions on central nervous system neurones
in animal studies; e.g., kappa-bungarotoxin is known to block
central post-synaptic nAChRs [149], alpha-cobratoxin can pro-
duce central pain-relieving actions, probably via cholinergic
pathways [195], beta-bungarotoxin affects neurotransmitter stor-
age and release in central synaptosomes [196,197], waglerin-1
inhibits GABAergic transmission [198,199], and dendrotoxins
have been shown to produce electrocortical convulsions, EEG
discharges, and neuronal damage [200–203]. In addition, several
muscarinic toxins have been identified from Dendroaspis spp.
[142,204]. While the pathological significance of these toxic effects
in humans is not clear, these findings clearly demonstrate the
possibility of neurotoxins affecting the central nervous system.
There are several reports of snake neurotoxins interacting with the
blood-brain barrier, which increase the likelihood of in vivo direct
central neurotoxic effects [205–210].
Autonomic involvement, especially parasympathetic denerva-
tion effects, are reported in several case series and case reports,
and almost all these reports are following krait bites [10,11,15,18].
This is likely to be related to defective ACh transmission at
parasympathetic nerve terminals, but the exact mechanisms have
not been identified. Neurotoxins have been shown to bind to
nAChRs in autonomic ganglia but the significance of this in
humans is not clear [149,150]. In addition, a few cases of acute
neuropathy have been reported following envenoming by Russell’s
viper (Daboia russelii) [72,74] and Eastern coral snake (Micrurus
fulvius) [48].
Delayed Neurological Manifestations
There are several reports of delayed neurological manifestations
after snake envenomation. Some are reports of persistence of
neurological deficits which first developed during the acute stage.
Distinction from critical illness neuropathy and myopathy may be
difficult when symptoms are first noticed soon after recovery from
the acute phase, especially with a background of ventilation, ICU
care, or sepsis [28,211]. There are several other reports of
neurological deficits developing at variable time points after
recovery from the acute phase of envenoming. Some of the reports
are confined to reporting of prolonged symptoms [11], and
objective documentations with neurophysiological assessments are
rare. In a series of 210 patients bitten by the common krait
(Bungarus caeruleus), 38 patients had delayed neurological deficits.
Fourteen of them had nerve conduction defects that lasted for 2
weeks to 6 months before complete recovery [10]. There are
several reports suggestive of polyneuropathy after the acute phase
of envenoming, with persistence of symptoms for several months
[9,65]. Several cases of possible Guillain-Barre´ syndrome (GBS)
have been reported. One patient developed motor and sensory
neuropathy 2 weeks after an unidentified snakebite and treatment
with antivenom and tetanus toxoid. His clinical, biochemical, and
electrophysiological features were suggestive of GBS [212].
Another report is of a patient who had acute neurotoxicity and
respiratory arrest after a krait bite and developed quadriparesis 3
weeks later with elevated CSF protein and evidence of a
sensorimotor axonal-type polyneuropathy [22]. However, GBS
seems unlikely here as he had a coma with dilated pupils. Perhaps
the most interesting report is by Neil et al. (2012) who describe a
case of GBS after a bite by Vipera aspis. They have demonstrated a
potential immunological basis for the syndrome, with cross-
reactivity shown between glycosidic epitopes of venom proteins
and neuronal GM2 ganglioside, without evidence of direct
neurotoxicity of the venom [80].
There are few robust studies of long-term neurological effects.
In the first detailed clinical and neurophysiological study of long-
term neurological deficits, Bell et al. studied 26 asymptomatic
survivors who had evidence of neurotoxicity during acute
envenomation one year earlier [213]. Significant differences were
noted in some neurophysiological parameters compared with
controls. These included prolongation of sensory, motor, and F-
wave latencies, and reduction of conduction velocities. The
changes were more marked in the upper limbs than the lower
limbs, suggesting a systemic effect related to envenoming rather
than local neurological damage, as all cases in the study were
bitten on the lower limb. No abnormalities were seen on repetitive
nerve stimulation, indicating lack of residual deficits in neuro-
muscular junction transmission. Taken together, the results were
suggestive of a non-length-dependent demyelinating-type poly-
neuropathy. The neurophysiological abnormalities were not
typical of a toxin-mediated neuropathy, which usually would be
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associated with axonal damage. Interestingly, abnormalities in
nerve conduction were only seen in those with presumed elapid
bites [213].
The factors responsible for the causation of long-term neuro-
logical effects need further study. Persistent axonal damage due to
neurotoxins, and delayed immune-mediated reactions to toxins or
antivenom are possible explanations. There is also some experi-
mental evidence for delayed neuropathic effects. In their report of
beta-bungarotoxin–induced toxicity in rats, Prasarnpun et al.
observed loss of myelinated axons at 6 months after inoculation
[109].
Discussion
Although the clinical manifestations of acute neuromuscular
weakness with respiratory involvement are well recognised, it is
surprising how many questions remain unanswered regarding
neurotoxicity. This lack of clarity may at least partly be explained
by the emerging evidence that has led to an increased
understanding of neuromuscular transmission. This suggests that
previously held traditional models of two different types of
neurotoxicity (pre-synaptic or post-synaptic) are inadequate to
explain all of the differences seen in symptom evolution and
recovery, patterns of weakness, respiratory involvement, and
responses to antivenom or AChEI therapy. For example, it is
becoming clear that many of the post-synaptic toxins produce
nearly irreversible binding, and long-lasting effects. The impor-
tance of the reversibility of post-synaptic toxicity, and the potential
for blockage of pre-synaptic nAChRs by ‘‘post-synaptic’’ toxins
after envenoming have not been addressed in adequate detail.
This variability in toxicity may partly explain the differences in the
pattern of envenomation by different species in different
geographical regions, and it is highly likely that the presence of
a number of different toxins in one venom also contributes.
Detailed analysis of venoms from different snake species from
different regions may help further elucidate these.
In addition to neuromuscular failure, several other interesting
acute and delayed neurological manifestations have been de-
scribed after snake envenomation, and there is very little
understanding of their pathophysiological basis. These are further
pointers to the diversity of the types of neurotoxicity produced by
different snake species. There is no agreed time cut-off for
classifying neurological manifestations into ‘‘acute’’ and ‘‘delayed/
late.’’ There is a clear need for a uniform classification of delayed
neurological manifestations. We propose that changes be classified
as acute (onset within the first 2 weeks after snakebite, which may
persist until late stages), delayed (onset within 2–8 weeks), and late
(onset after 8 weeks of envenoming).
Improved case definitions are the key to a better understanding
of neurotoxicity from different snakes. This can only be achieved
by either the identification of dead snakes or the use of laboratory
or near-patient detection of venom antigen. Further development
of such techniques for developing countries where snakebites are
common is vital to allow accurate and meaningful clinical
descriptions of neurotoxicity.
Given the high morbidity and mortality, better treatment
options are clearly needed in neurotoxic envenoming. There are
several exciting reports of the use of plant extracts in the treatment
of neurotoxicity [214–222]. Although promising, much more
research is needed before these may become therapeutic options.
Until such innovative treatments are available, much can be
achieved by public health measures such as better education with
emphasis on early hospitalization, improved availability of
antivenom and intensive care facilities in areas where snakebite
is common, and international collaborative efforts to develop such
strategies in these resource-limited settings. Development of more
effective and safer antivenoms including monospecific antivenoms
and Fab fragments, and a better understanding of the cross-
neutralisations possible with available antivenom, may help to
optimize the use of antivenom in neurotoxicity [182,223–226].
Given the lack of clarity over mechanisms of neurotoxicity, the
lack of consensus on the value of antivenom or AChEI therapy in
snake envenoming is not surprising. Conflicting reports of their
efficacy are likely to reflect different mechanisms of neurotoxicity
produced by different snake species, and potentially, variations in
antivenom efficacy and time of administration. Models to predict
type of toxicity, and a better understanding of the type of toxicity
produced by different species, would perhaps enable better use of
these treatment strategies. More data are needed on their efficacy,
and may be obtained only from clinical trials in envenomation by
different snake species. Electrophysiological studies may also be
Key Learning Points
1. Snake venoms are complex mixtures of different toxins,
and each neurotoxin has diverse neurotoxic effects.
2. There is considerable geographical, interspecies, intra-
species, as well as possibly ontogenetic variation in
neurotoxicity with snake envenoming.
3. Accurate identification of envenoming snakes and
uniform case definitions are needed to improve compa-
rability of different reports of neurotoxic envenoming.
4. There are many interesting acute and delayed neurotoxic
manifestations other than neuromuscular weakness, and
these may reveal valuable information that may lead to a
better understanding of other neurological diseases.
5. The evidence for antivenom and AChEIs in treatment of
neurotoxic envenoming is not strong, and large ran-
domized trials are urgently needed.
Five Key Papers in the Field
1. Prasarnpun S, Walsh J, Awad SS, Harris JB (2005)
Envenoming bites by kraits: the biological basis of
treatment-resistant neuromuscular paralysis. Brain 128:
2987–2996.
2. Lee C, Chen D, Katz RL (1977) Characteristics of
nondepolarizing neuromuscular block: (I) post-junctional
block by alpha-bungarotoxin. Can Anaesth Soc J 24: 212–
219.
3. Kularatne SA (2002) Common krait (Bungarus caeruleus)
bite in Anuradhapura, Sri Lanka: a prospective clinical
study, 1996–98. Postgrad Med J 78: 276–280.
4. Lalloo DG, Trevett AJ, Korinhona A, Nwokolo N,
Laurenson IF, et al. (1995) Snake bites by the Papuan
taipan (Oxyuranus scutellatus canni): paralysis, hemostatic
and electrocardiographic abnormalities, and effects of
antivenom. Am J Trop Med Hyg 52: 525–531.
5. Watt G, Theakston RD, Hayes CG, Yambao ML, Sangalang
R, et al. (1986) Positive response to edrophonium in
patients with neurotoxic envenoming by cobras (Naja
naja philippinensis). A placebo-controlled study. N Engl J
Med 315: 1444–1448.
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valuable in helping us to understand the complex processes in
human neurological envenoming.
Snake neurotoxins have contributed significantly to our
understanding of neuromuscular transmission and receptor
function, and recent studies have highlighted many of their
other properties, e.g., the ability to enter actively proliferating
cells, nuclear localization, preferential binding in specific cell
division phases, inhibition of apoptosis, anti-inflammatory and
analgesic actions, and antimicrobial effects [183,195,227–232].
More research into these fascinating molecules and their diverse
actions would not only help us improve management of
neurotoxic envenoming, but may also enable their use as
potential treatments for infections, cancer, and various neuro-
logical disorders.
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